PETACH TIKVA, Israel, July 23, 2015 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company has been invited by Israel's Office of the Chief Scientist to join a delegation comprised of Israel's leading life sciences companies to participate in industry visits, presentation sessions, and networking events focused on finding R&D partners and business opportunities in Japan. Can-Fite's Director of Business Development, Dr. Sari Fishman, will participate in meetings in Tokyo on July 28 through 30, 2015.
The Life Sciences Delegation is being organized under the framework of the new Japan-Israel R&D Cooperation Program, which provides funding support and partner matching assistance for collaborative R&D projects between Israeli and Japanese companies. Organizers of the delegation include the Office of the Chief Scientist and MATIMOP-The Israeli Industry Center for R&D, the Foreign Trade Administration, and the Economic Department at the Embassy of Israel in Tokyo, together with the Japanese Ministry of Economy, Trade and Industry (METI) and NEDO, the New Energy and Industrial Technology Development Organization in Japan.
"Can-Fite is honored to be invited by our Chief Scientist, Avi Hasson, to participate in this scientific and trade delegation. We are currently in due diligence talks with companies in Japan who are interested in our technologies," stated Can-Fite CEO Dr. Pnina Fishman. "These additional meetings during the delegation visit, with some of the top companies in Japan, are intended to support our efforts to enter into an agreement with the right partner in this very significant healthcare market."
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company's CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite's liver cancer drug CF102 is commencing Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information please visit: www.can-fite.com
This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Can-Fite BioPharma Ltd.